Clinical trials for lung cancer
130 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 2
Lung cancer
#NCT05565378
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
Systemic Treatment-Naive
PDL1 Positive (>= 50%)
EGFR
ALK
Immunotherapy
Centre Hospitalier de Cornouaille (Quimper), Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil (Strasbourg), Centre Hospitalier Universitaire de Bordeaux (Bordeaux), CHU Caen Normandie (Caen), Hôpital de la Timone AP-HM (Marseille)
GlaxoSmithKline
Phase 2
Lung cancer
#NCT05403385
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Locally Advanced
Metastatic
Immunotherapy
EGFR
ALK
Systemic Treatment-Naive
CHU Caen Normandie (Caen), Centre Hospitalier Universitaire de Nantes (Nantes), Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Centre Léon Bérard (Lyon), Hôpital de la Timone AP-HM (Marseille) (and 4 more...)
iTeos Belgique SA
Phase 2
Lung cancer
#NCT05325866
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
Immunotherapy
Chemotherapy
Targeted therapy
Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Centre Hospitalier Universitaire de Besançon (Besançon), Centre Oscar Lambret (Lille), Institut Paoli-Calmettes (Marseille), Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite) (and 2 more...)
Amgen
Phase 2
Lung cancer
#NCT05180474
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Systemic Treatment-Naive
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Besançon (Besançon), Institut Curie - Paris (Paris), Institut Bergonié (Bordeaux), Hôpital Cochin (Paris ), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers) (and 3 more...)
Genmab
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
#NCT05118789
SCLC (Small Cell Lung Cancer)
Mesothelium
Locally Advanced
Metastatic
Metastatic Castration-resistant
ROS-1
Other mutation
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif), Centre Hospitalier Universitaire - Site Hôtel Dieu (Nantes), Centre Hospitalier Universitaire de Toulouse (Toulouse)
Nuvalent Inc.
Phase 2
Lung cancer
#NCT05118789
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
ROS-1
Targeted therapy
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif), Centre Hospitalier Universitaire - Site Hôtel Dieu (Nantes), Centre Hospitalier Universitaire de Toulouse (Toulouse)
Nuvalent Inc.
Phase 2
Lung cancer
#NCT05118789
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
ROS-1
Systemic Treatment-Naive
Chemotherapy
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif), Centre Hospitalier Universitaire - Site Hôtel Dieu (Nantes), Centre Hospitalier Universitaire de Toulouse (Toulouse)
Nuvalent Inc.
Phase 2
Lung cancer
#NCT05061550
NSCLC (Non-Small Cell Lung Cancer)
Localized
Locally Advanced
Systemic Treatment-Naive
Systemic Treatment-Naive
EGFR
ALK
Centre Hospitalier Universitaire Dupuytren (Limoges), Centre Hospitalier Universitaire de Rouen (Rouen), Hôpital Foch (Suresnes), Hôpital Sainte Musse (Toulon), Centre Hospitalier d'Avignon (Avignon)
AstraZeneca
Phase 2
Lung cancer
#NCT04931654
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Non-squamous NSCLC
Locally Advanced
Metastatic
Systemic Treatment-Naive
PDL1 Positive (>= 50%)
EGFR
BRAF
MET
ALK
ROS-1
NTRK-1/2/3
KRAS G12C
Centre Hospitalier Universitaire de Bordeaux (Bordeaux), Hôpital de la Timone AP-HM (Marseille)
AstraZeneca
Phase 2
Lung cancer
#NCT04931654
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Non-squamous NSCLC
Locally Advanced
Metastatic
Immunotherapy
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
EGFR
BRAF
MET
ALK
ROS-1
NTRK-1/2/3
KRAS G12C
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Bordeaux (Bordeaux), Hôpital de la Timone AP-HM (Marseille)
AstraZeneca